Matches in Wikidata for { <http://www.wikidata.org/entity/Q93264391> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q93264391 description "article scientifique publié en 2020" @default.
- Q93264391 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q93264391 description "bài báo khoa học" @default.
- Q93264391 description "scientific article published on 27 April 2020" @default.
- Q93264391 description "wetenschappelijk artikel" @default.
- Q93264391 description "наукова стаття, опублікована 27 квітня 2020" @default.
- Q93264391 name "Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine" @default.
- Q93264391 name "Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine" @default.
- Q93264391 type Item @default.
- Q93264391 label "Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine" @default.
- Q93264391 label "Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine" @default.
- Q93264391 prefLabel "Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine" @default.
- Q93264391 prefLabel "Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine" @default.
- Q93264391 P1433 Q93264391-8098E727-1542-48E4-ADFB-21DABD1C44DC @default.
- Q93264391 P1476 Q93264391-CABD99CA-F866-41A1-B20B-8ECB21588BCE @default.
- Q93264391 P2093 Q93264391-171B69B2-791F-4F66-8CDA-F86F977E8507 @default.
- Q93264391 P2093 Q93264391-252F9697-AFE1-4B37-9D24-F48F286FCE6B @default.
- Q93264391 P2093 Q93264391-618AA10B-A2FF-48A6-802D-A51CDC3C6ED3 @default.
- Q93264391 P2093 Q93264391-630FA907-82F1-4CB8-807D-862BFF0EC372 @default.
- Q93264391 P2093 Q93264391-76DC55CE-2B26-4623-9926-6313623CF171 @default.
- Q93264391 P2093 Q93264391-8001BEA1-7B26-472C-ACFA-BE1C869DA3FC @default.
- Q93264391 P2093 Q93264391-A88A6C5E-F330-4217-9E2C-1E9B78B1C3F0 @default.
- Q93264391 P2093 Q93264391-E8826EA7-6CE0-43F7-BDBA-F786E9107D50 @default.
- Q93264391 P275 Q93264391-73554554-00F3-4B9E-95E0-6B73EADB7333 @default.
- Q93264391 P304 Q93264391-2C114D6A-38AB-4067-994C-08F51DAB8115 @default.
- Q93264391 P31 Q93264391-A34D2CBD-83E8-4596-9F69-33D4A51E129A @default.
- Q93264391 P356 Q93264391-50628491-AE83-4294-AFF9-FBCEBB9B81D5 @default.
- Q93264391 P50 Q93264391-74296A37-C09D-4E4E-9509-A52EF5E67D2E @default.
- Q93264391 P577 Q93264391-F36C5173-188C-4DE0-9249-6B07848874F9 @default.
- Q93264391 P6216 Q93264391-CE1F3FCA-6DAA-4B66-BC82-F074B913A374 @default.
- Q93264391 P698 Q93264391-24441277-D68D-40AA-834F-DC888BAE10FD @default.
- Q93264391 P921 Q93264391-A27D5F25-E8FB-4AD6-9740-620A51C5F4D4 @default.
- Q93264391 P932 Q93264391-1291CADE-9118-4FA7-B26F-17757D5F65B5 @default.
- Q93264391 P356 0333102420920642 @default.
- Q93264391 P698 32340471 @default.
- Q93264391 P1433 Q5063251 @default.
- Q93264391 P1476 "Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine" @default.
- Q93264391 P2093 "Brian A Moser" @default.
- Q93264391 P2093 "Eric M Pearlman" @default.
- Q93264391 P2093 "Greg Anglin" @default.
- Q93264391 P2093 "James M Martinez" @default.
- Q93264391 P2093 "Michael E Hodsdon" @default.
- Q93264391 P2093 "Nada Hindiyeh" @default.
- Q93264391 P2093 "Sandra Garces" @default.
- Q93264391 P2093 "William Kielbasa" @default.
- Q93264391 P275 Q34179348 @default.
- Q93264391 P304 "333102420920642" @default.
- Q93264391 P31 Q13442814 @default.
- Q93264391 P356 "10.1177/0333102420920642" @default.
- Q93264391 P50 Q108017258 @default.
- Q93264391 P577 "2020-04-27T00:00:00Z" @default.
- Q93264391 P6216 Q50423863 @default.
- Q93264391 P698 "32340471" @default.
- Q93264391 P921 Q42824827 @default.
- Q93264391 P932 "7469706" @default.